Depression in cognitive impairment

Current Psychiatry Reports

Volumn 15, Issue 9, 2013, Pages

  Pellegrino, Laurel D ^a   Peters, Matthew E ^a   Lyketsos, Constantine G ^a   Marano, Christopher M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

AD; Alzheimer's disease; Dementia; Depression; ECT; Electroconvulsive therapy; Genetics; Geriatric disorders; MCI; Mild cognitive impairment; Neuroimaging; Neuropsychiatric symptoms; Neurotrophins; Pharmacologic treatments; Psychiatry

Indexed keywords

ANTIDEPRESSANT AGENT;

COGNITIVE DEFECT; DEPRESSION; ELECTROCONVULSIVE THERAPY; HUMAN; METHODOLOGY; PATHOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR; DEPRESSIVE DISORDER; PROCEDURES; PSYCHOLOGY;

ANTIDEPRESSIVE AGENTS; COGNITION DISORDERS; DEPRESSIVE DISORDER; ELECTROCONVULSIVE THERAPY; HUMANS; RISK FACTORS;

EID: 84881114609     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-013-0384-1     Document Type: Article

References (78)

1. Kessler RC, Petukhova M, Sampson NA, et al. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the united states. Int J Methods Psychiatr Res. 2012;21:169-84.
2. Morrell CJ, Curran S, Topping A, et al. Identification of depressive disorder among older people in care homes - a feasibility study. Prim Health Care Res Dev. 2011;12:255-65.
3. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the united states: The aging, demographics, and memory study. Neuroepidemiology. 2007;29:125-32. (Pubitemid 350191430)
4. -2012 Alzheimer's disease facts and figures. Washington, D.C.: Alzheimer's Association. 2012.
5. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol. 1999;56:303-8. (Pubitemid 29120227)
6. Tuokko H, Frerichs RJ. Cognitive impairment with no dementia (CIND): Longitudinal studies, the findings, and the issues. Clin Neuropsychol. 2000;14:504-25.
7. Winter Y, Korchounov A, Zhukova TV, Bertschi NE. Depression in elderly patients with alzheimer dementia or vascular dementia and its influence on their quality of life. J Neurosci Rural Pract. 2011;2:27-32.
8. Sheehan BD, Lall R, Stinton C, et al. Patient and proxy measurement of quality of life among general hospital in-patients with dementia. Aging Ment Health. 2012;16:603-7.
9. Karttunen K, Karppi P, Hiltunen A, et al. Neuropsychiatric symptoms and quality of life in patients with very mild and mild alzheimer's disease. Int J Geriatr Psychiatry. 2011;26:473-82.
10. Rapp MA, Schnaider-Beeri M, Wysocki M, et al. Cognitive decline in patients with dementia as a function of depression. Am J Geriatr Psychiatry. 2011;19:357-63.
11. Steffens DC, Otey E, Alexopoulos GS, et al. Perspectives on depression, mild cognitive impairment, and cognitive decline. Arch Gen Psychiatry. 2006;63:130-8. (Pubitemid 43213874)
12. Ownby RL, Crocco E, Acevedo A, et al. Depression and risk for alzheimer disease: Systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006;63:530-8.
13. Butters MA, Young JB, Lopez O, et al. Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin Neurosci. 2008;10:345-57.
14. Byers AL, Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol. 2011;7:323-31.
15. Alexopoulos GS, Meyers BS, Young RC, et al. The course of geriatric depression with "reversible dementia": A controlled study. Am J Psychiatry. 1993;150:1693-9. (Pubitemid 23325953)
16. Alexopoulos GS, Young RC, Meyers BS. Geriatric depression: Age of onset and dementia. Biol Psychiatry. 1993;34:141-5. (Pubitemid 23257739)
17. Bhalla RK, Butters MA, Mulsant BH, et al. Persistence of neuropsychologic deficits in the remitted state of late-life depression. Am J Geriatr Psychiatry. 2006;14:419-27.
18. • Diniz BS, Butters MA, Albert SM, et al. Late-life depression and risk of vascular dementia and alzheimer's disease: Systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013;202:329-35. This meta-analysis of 23 studies concluded that late-life depression is associated with an increased risk for all-cause dementia, vascular dementia, and AD.
19. Rapp MA, Schnaider-Beeri M, Grossman HT, et al. Increased hippocampal plaques and tangles in patients with alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry. 2006;63:161-7. (Pubitemid 43213877)
20. Alexopoulos GS, Meyers BS, Young RC, et al. 'Vascular depression' hypothesis. Arch Gen Psychiatry. 1997;54:915-22. (Pubitemid 128719702)
21. Krishnan KR, Hays JC, Blazer DG. MRI-defined vascular depression. Am J Psychiatry. 1997;154:497-501. (Pubitemid 27147602)
22. Culang-Reinlieb ME, Johnert LC, Brickman AM, et al (2010) MRI-defined vascular depression: A review of the construct. Int J Geriatr Psychiatry
23. • Barnes DE, Yaffe K. The projected effect of risk factor reduction on alzheimer's disease prevalence. Lancet Neurol. 2011;10:819-28. This review summarizes the evidence regarding modification of seven potentially modifiable risk factors for AD: diabetes, midlife hypertension, midlife obesity, smoking, depression, cognitive inactivity or low educational attainment, and physical inactivity. Based on these analyses, up to half of AD cases worldwide and in the US are potentially attributable to these seven factors.
24. Kessing LV, Forman JL, Andersen PK. Do continued antidepressants protect against dementia in patients with severe depressive disorder? Int Clin Psychopharmacol. 2011;26:316-22.
25. Goveas JS, Hogan PE, Kotchen JM, et al. Depressive symptoms, antidepressant use, and future cognitive health in postmenopausal women: The women's health initiative memory study. Int Psychogeriatr. 2012;24:1252-64.
26. Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-14. (Pubitemid 24382728)
27. Peters ME, Rosenberg PB, Steinberg M, et al. Prevalence of neuropsychiatric symptoms in CIND and its subtypes: The cache county study. Am J Geriatr Psychiatry. 2012;20:416-24.
28. Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: The cache county study. Int J Geriatr Psychiatry. 2008;23:170-7. (Pubitemid 351308497)
29. Hidaka S, Ikejima C, Kodama C, et al. Prevalence of depression and depressive symptoms among older japanese people: Comorbidity of mild cognitive impairment and depression. Int J Geriatr Psychiatry. 2012;27:271-9.
30. Garre-Olmo J, Lopez-Pousa S, Vilalta-Franch J, et al. Evolution of depressive symptoms in alzheimer disease: One-year follow-up. Alzheimer Dis Assoc Disord. 2003;17:77-85. (Pubitemid 36736841)
31. Starkstein SE, Mizrahi R, Garau L. Specificity of symptoms of depression in alzheimer disease: A longitudinal analysis. Am J Geriatr Psychiatry. 2005;13:802-7.
32. Lyketsos CG, Breitner JC, Rabins PV. An evidence-based proposal for the classification of neuropsychiatric disturbance in alzheimer's disease. Int J Geriatr Psychiatry. 2001;16:1037-42. (Pubitemid 33089267)
33. Olin JT, Schneider LS, Katz IR, et al. Provisional diagnostic criteria for depression of alzheimer disease. Am J Geriatr Psychiatry. 2002;10:125-8. (Pubitemid 34685625)
34. Vilalta-Franch J, Garre-Olmo J, Lopez-Pousa S, et al. Comparison of different clinical diagnostic criteria for depression in alzheimer disease. Am J Geriatr Psychiatry. 2006;14:589-97. (Pubitemid 44036483)
35. Teng E, Ringman JM, Ross LK, et al. Diagnosing depression in alzheimer disease with the national institute of mental health provisional criteria. Am J Geriatr Psychiatry. 2008;16:469-77.
36. Starkstein SE, Dragovic M, Jorge R, et al. Diagnostic criteria for depression in alzheimer disease: A study of symptom patterns using latent class analysis. Am J Geriatr Psychiatry. 2011;19:551-8.
37. Panza F, Frisardi V, Seripa D, et al. Metabolic syndrome, mild cognitive impairment, and dementia. Curr Alzheimer Res. 2011;8:492-509.
38. Fritze F, Ehrt U, Sonnesyn H, et al. Depression in mild dementia: Associations with diagnosis, APOE genotype and clinical features. Int J Geriatr Psychiatry. 2011;26:1054-61.
39. Kim JM, Stewart R, Kim SY, et al. Synergistic associations of depression and apolipoprotein E genotype with incidence of dementia. Int J Geriatr Psychiatry. 2011;26:893-8.
40. Caracciolo B, Backman L, Monastero R, et al. The symptom of low mood in the prodromal stage of mild cognitive impairment and dementia: A cohort study of a community dwelling elderly population. J Neurol Neurosurg Psychiatry. 2011;82:788-93.
41. den Heijer T, Tiemeier H, Luijendijk HJ, et al. A study of the bidirectional association between hippocampal volume on magnetic resonance imaging and depression in the elderly. Biol Psychiatry. 2011;70:191-7.
42. Steffens DC, McQuoid DR, Payne ME, Potter GG. Change in hippocampal volume on magnetic resonance imaging and cognitive decline among older depressed and nondepressed subjects in the neurocognitive outcomes of depression in the elderly study. Am J Geriatr Psychiatry. 2011;19:4-12.
43. Tsopelas C, Stewart R, Savva GM, et al. Neuropathological correlates of late-life depression in older people. Br J Psychiatry. 2011;198:109-14.
44. Lee GJ, Lu PH, Hua X, et al. Depressive symptoms in mild cognitive impairment predict greater atrophy in alzheimer's disease-related regions. Biol Psychiatry. 2012;71:814-21.
45. O'Brien J, Perry R, Barber R, et al. The association between white matter lesions on magnetic resonance imaging and noncognitive symptoms. Ann NY Acad Sci. 2000;903:482-9. (Pubitemid 30251593)
46. Mueller SG, Mack WJ, Mungas D, et al. Influences of lobar gray matter and white matter lesion load on cognition and mood. Psychiatry Res. 2010;181:90-6.
47. Wang L, Potter GG, Krishnan RK, et al. Neural correlates associated with cognitive decline in late-life depression. Am J Geriatr Psychiatry. 2012;20:653-63.
48. Kang JY, Lee JS, Kang H, et al. Regional cerebral blood flow abnormalities associated with apathy and depression in alzheimer disease. Alzheimer Dis Assoc Disord. 2012;26:217-24.
49. Kumar A, Kepe V, Barrio JR, et al. Protein binding in patients with late-life depression. Arch Gen Psychiatry. 2011;68:1143-50.
50. Taylor WD, Zuchner S, McQuoid DR, et al. Allelic differences in the brain-derived neurotrophic factor Val66Met polymorphism in late-life depression. Am J Geriatr Psychiatry. 2007;15:850-7.
51. Borroni B, Grassi M, Archetti S, et al. BDNF genetic variations increase the risk of alzheimer's disease-related depression. J Alzheimers Dis. 2009;18:867-75.
52. Borroni B, Archetti S, Costanzi C, et al. Role of BDNF Val66Met functional polymorphism in alzheimer's disease-related depression. Neurobiol Aging. 2009;30:1406-12.
53. Zhang L, Fang Y, Zeng Z, et al. BDNF gene polymorphisms are associated with alzheimer's disease-related depression and antidepressant response. J Alzheimers Dis. 2011;26:523-30.
54. Caraci F, Copani A, Nicoletti F, Drago F. Depression and alzheimer's disease: Neurobiological links and common pharmacological targets. Eur J Pharmacol. 2010;626:64-71.
55. Caraci F, Bosco P, Signorelli M, et al. The CC genotype of transforming growth factor-beta1 increases the risk of late-onset alzheimer's disease and is associated with AD-related depression. Eur Neuropsychopharmacol. 2012;22:281-9.
56. Rosenberg PB, Mielke MM, Lyketsos CG. Caregiver assessment of patients' depression in alzheimer disease: Longitudinal analysis in a drug treatment study. Am J Geriatr Psychiatry. 2005;13:822-6.
57. Steinberg M, Sheppard JM, Tschanz JT, et al. The incidence of mental and behavioral disturbances in dementia: The cache county study. J Neuropsychiatry Clin Neurosci. 2003;15:340-5. (Pubitemid 36999377)
58. •• Rosenberg PB, Drye LT, Martin BK, et al. Sertraline for the treatment of depression in alzheimer disease. Am J Geriatr Psychiatry. 2010;18:136-45. This study found that sertraline did not demonstrate efficacy for the treatment of depression in patients with AD. In addition, its use was associated with an increased incidence of adverse events. The study concluded that selective serotonin reuptake inhibitors may be of limited value for treating depression in patients with AD.
59. Weintraub D, Rosenberg PB, Drye LT, et al. Sertraline for the treatment of depression in alzheimer disease: Week-24 outcomes. Am J Geriatr Psychiatry. 2010;18:332-40.
60. Munro CA, Longmire CF, Drye LT, et al. Cognitive outcomes after sertaline treatment in patients with depression of alzheimer disease. Am J Geriatr Psychiatry. 2012;20:1036-44.
61. Drye LT, Martin BK, Frangakis CE, et al. Do treatment effects vary among differing baseline depression criteria in depression in alzheimer's disease study +/- 2 (DIADS-2)? Int J Geriatr Psychiatry. 2011;26:573-83.
62. Peters ME, Vaidya V, Drye LT, et al. Sertraline for the treatment of depression in alzheimer disease: Genetic influences. J Geriatr Psychiatry Neurol. 2011;24:222-8.
63. •• Banerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): A randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011;378:403-11. This study on the utility of treatment with mirtazapine vs. sertraline vs. both for the treatment of depression in AD found absence of benefit compared with placebo and increased risk of adverse events. The study concluded that the use of antidepressants for first-line treatment of depression in AD should be reconsidered.
64. Brodaty H. Antidepressant treatment in alzheimer's disease. Lancet. 2011;378:375-6.
65. Henry G, Williamson D, Tampi RR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Demen. 2011;26:169-83.
66. Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: Population based cohort study. BMJ. 2011;343:d4551.
67. Sterke CS, Ziere G, van Beeck EF, et al. Dose-response relationship between selective serotonin re-uptake inhibitors and injurious falls: A study in nursing home residents with dementia. Br J Clin Pharmacol. 2012;73:812-20.
68. Salzman C, Wong E, Wright BC. Drug and ECT treatment of depression in the elderly, 1996-2001: A literature review. Biol Psychiatry. 2002;52:265-84. (Pubitemid 35232093)
69. Rao V, Lyketsos CG. The benefits and risks of ECT for patients with primary dementia who also suffer from depression. Int J Geriatr Psychiatry. 2000;15:729-35.
70. Hausner L, Damian M, Sartorius A, Frolich L. Efficacy and cognitive side effects of electroconvulsive therapy (ECT) in depressed elderly inpatients with coexisting mild cognitive impairment or dementia. J Clin Psychiatry. 2011;72:91-7.
71. Oudman E. Is electroconvulsive therapy (ECT) effective and safe for treatment of depression in dementia? A short review. J ECT. 2012;28:34-8.
72. Thune-Boyle IC, Iliffe S, Cerga-Pashoja A, et al. The effect of exercise on behavioral and psychological symptoms of dementia: Towards a research agenda. Int Psychogeriatr. 2012;24:1046-57.
73. Fan JT, Chen KM. Using silver yoga exercises to promote physical and mental health of elders with dementia in long-term care facilities. Int Psychogeriatr. 2011;23:1222-30.
74. Cooper C, Mukadam N, Katona C, et al. Systematic review of the effectiveness of non-pharmacological interventions to improve quality of life of people with dementia. Int Psychogeriatr. 2012;24:856-70.
75. Verkaik R, Francke AL, van Meijel B, et al. The effects of a nursing guideline on depression in psychogeriatric nursing home residents with dementia. Int J Geriatr Psychiatry. 2011;26:723-32.
76. van Beek AP, Frijters DH, Wagner C, et al. Social engagement and depressive symptoms of elderly residents with dementia: A cross-sectional study of 37 long-term care units. Int Psychogeriatr. 2011;23:625-33.
77. Marano C, Rosenberg P, Lyketsos C. Depression in dementia. In: Lavretsky H, Sajatovic M, Reynolds C, editors. Late-life Mood Disorders. New York: Oxford: New York: Oxford University Press; 2013.
78. Brodaty H. Antidepressant treatment in alzheimer's disease. Lancet. 2011;378:375-6.